Lyell to cut staff by 25%, CMO departs

08 Nov 2023
firstwordpharma.com
Cell TherapyPhase 1ImmunotherapyPhase 2
Lyell Immunopharma disclosed that it is letting go of about a quarter of its workforce by year-end and has scaled down investment in certain early-stage research programmes, actions it says will allow it to fund operations through to 2027. Chief medical officer Tina Albertson is also leaving the company.
"As we continue to generate clinical data from our two lead programmes, we have also taken important steps toward reducing costs and manufacturing time for cell therapies through our proof-of-concept CAR T-cell manufacturing collaboration with Cellares and advances in our Epi-R P2 manufacturing process," stated CEO Lynn Seely. She added that the company has decided to prioritise investments in its clinical-stage programmes instead.
Last year's GSK bow-out
According to its website, the company is evaluating the CAR-T cell therapy LYL797 in Phase I for patients with ROR1-positive triple-negative breast cancerROR1-positive triple-negative breast cancer or non-small-cell lung cancer. The second Phase I programme is LYL845, an autologous TIL therapy produced with Lyell's Epi-R epigenetic reprogramming protocol. Seely said Lyell remains on track to present initial data from each of its two lead Phase I projects next year.
The layoffs and pipeline prioritisation come roughly a year after GSK discontinued its development of drugs targeting NY-ESO-1, including the second-generation candidates incorporating Lyell's Epi-R technologies LYL132 and LYL331. When Lyell made the disclosure in October last year, it noted that GSK still remained a "significant stockholder" of the company.
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Organizations
Indications
Targets
Drugs
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.